BeOne Medicines (BEIGF) Change in Cash (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Change in Cash data on file, last reported at $243.8 million in Q1 2026.

• Change in Cash for Q1 2026 came in at $243.8 million, up 325.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 939.04% YoY), and the FY2025 annual result was $2.0 billion, up 460.15% from the prior year.
• Change in Cash retreated to $243.8 million in Q1 2026 per BEIGF's latest filing, from $499.1 million in the prior quarter.
• Over five years, Change in Cash peaked at $1.3 billion in Q3 2025 and troughed at -$378.5 million in Q1 2024.
• A 5-year average of $27.7 million and a median of -$74.7 million in 2024 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2023 and 2025: Change in Cash tumbled 1064.93% in 2023, then soared 1286.91% in 2025.
• A 5-year view of Change in Cash shows it stood at -$325.5 million in 2022, then soared by 132.29% to $105.1 million in 2023, then plunged by 171.06% to -$74.7 million in 2024, then surged by 768.32% to $499.1 million in 2025, then tumbled by 51.16% to $243.8 million in 2026.
• Business Quant data shows BEIGF's Change in Cash at $243.8 million in Q1 2026, $499.1 million in Q4 2025, and $1.3 billion in Q3 2025.